Literature DB >> 24722870

[B-lymphocytes as effectors and regulators in systemic lupus erythematosus].

T H Winkler1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722870     DOI: 10.1007/s00393-013-1295-6

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  11 in total

1.  Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity.

Authors:  Imtiaz M Mumtaz; Bimba F Hoyer; Daniel Panne; Katrin Moser; Oliver Winter; Qingyu Y Cheng; Taketoshi Yoshida; Gerd-R Burmester; Andreas Radbruch; Rudolf A Manz; Falk Hiepe
Journal:  J Autoimmun       Date:  2012-06-20       Impact factor: 7.094

Review 2.  Immunopathogenic mechanisms of systemic autoimmune disease.

Authors:  Marie Wahren-Herlenius; Thomas Dörner
Journal:  Lancet       Date:  2013-08-31       Impact factor: 79.321

3.  Signaling via the MyD88 adaptor protein in B cells suppresses protective immunity during Salmonella typhimurium infection.

Authors:  Patricia Neves; Vicky Lampropoulou; Elisabeth Calderon-Gomez; Toralf Roch; Ulrik Stervbo; Ping Shen; Anja A Kühl; Christoph Loddenkemper; Matthias Haury; Sergei A Nedospasov; Stefan H E Kaufmann; Ulrich Steinhoff; Dinis P Calado; Simon Fillatreau
Journal:  Immunity       Date:  2010-11-24       Impact factor: 31.745

4.  Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus.

Authors:  Lino L Teichmann; Dominik Schenten; Ruslan Medzhitov; Michael Kashgarian; Mark J Shlomchik
Journal:  Immunity       Date:  2013-03-14       Impact factor: 31.745

5.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus.

Authors:  Melissa R Arbuckle; Micah T McClain; Mark V Rubertone; R Hal Scofield; Gregory J Dennis; Judith A James; John B Harley
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

6.  The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis.

Authors:  Kirsten Neubert; Silke Meister; Katrin Moser; Florian Weisel; Damian Maseda; Kerstin Amann; Carsten Wiethe; Thomas H Winkler; Joachim R Kalden; Rudolf A Manz; Reinhard E Voll
Journal:  Nat Med       Date:  2008-06-08       Impact factor: 53.440

7.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Authors:  Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

8.  B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells.

Authors:  Tom A Barr; Ping Shen; Sheila Brown; Vicky Lampropoulou; Toralf Roch; Sarah Lawrie; Boli Fan; Richard A O'Connor; Stephen M Anderton; Amit Bar-Or; Simon Fillatreau; David Gray
Journal:  J Exp Med       Date:  2012-04-30       Impact factor: 14.307

9.  Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions.

Authors:  Ayumi Yoshizaki; Tomomitsu Miyagaki; David J DiLillo; Takashi Matsushita; Mayuka Horikawa; Evgueni I Kountikov; Rosanne Spolski; Jonathan C Poe; Warren J Leonard; Thomas F Tedder
Journal:  Nature       Date:  2012-10-14       Impact factor: 49.962

Review 10.  IL-10-producing regulatory B cells (B10 cells) in autoimmune disease.

Authors:  Ioannis Kalampokis; Ayumi Yoshizaki; Thomas F Tedder
Journal:  Arthritis Res Ther       Date:  2013-02-11       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.